A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis
NCT07270003
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Palmoplantar Pustulosis (PPP)
Interventions
DRUG:
Ivarmacitinib
Sponsor
Xijing Hospital